VBIV (VBI Vaccines) Short-Term Debt to Capital

The current management of VBI Vaccines Inc. (VBIV) is operating in a mode of judicial liquidation and patent sales, which is confirmed by the market price visualization, where the indicator stands at 0.00. The specifics of vaccine development make the business independent of market cycles, relying instead on long-term government contracts. Furthermore, the humanitarian status of medicine minimizes political risks, ensuring stable international partnerships within the legal frameworks of developed nations.

This indicator is calculated as the ratio of short-term liabilities to equity, measuring the company's dependence on short-term financing and the risk of shareholder value dilution. For VBI Vaccines Inc. (VBIV), this parameter is critical, as geopolitical instability and raw material supply chain disruptions from Asia could limit revenue, making the short-term debt-to-equity ratio a key marker of solvency.